| Code | CSB-RA011614MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to bermekimab, targeting interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B plays a critical role in initiating and amplifying inflammatory cascades by promoting fever, activating immune cells, and inducing the production of additional inflammatory mediators. Dysregulated IL1B signaling is implicated in numerous pathological conditions, including autoinflammatory diseases, hidradenitis suppurativa, metabolic disorders, cardiovascular disease, and various malignancies where chronic inflammation contributes to disease progression.
Bermekimab is a humanized IgG1 monoclonal antibody that specifically neutralizes IL1B, preventing its interaction with IL-1 receptors and subsequent downstream inflammatory signaling. This biosimilar antibody provides researchers with a valuable tool for investigating IL1B-mediated pathways, studying inflammatory disease mechanisms, and exploring therapeutic interventions in preclinical models. The antibody enables examination of IL1B blockade effects across diverse experimental systems, supporting translational research in immunology, inflammation biology, and therapeutic development programs.
There are currently no reviews for this product.